Dr. Tannenbaum recently led a team of international researchers to investigate which medications are most likely to affect amnestic (memory) or non-amnestic (attention, concentration, performance) brain functions. After analyzing the results from 162 experiments on medications with potential to bind to cholinergic, histamine, GABAergic or opioid receptors in the brain, Dr. Tannenbaum concluded that the episodic use of several medications can cause amnestic or non-amnestic deficits. This potential cause is often overlooked in persons who are otherwise in good health.

The 68 trials on benzodiazepines (which are often used to treat anxiety and insomnia) that were analyzed showed that these drugs consistently lead to impairments in memory and concentration, with a clear dose-response relationship. The 12 tests on antihistamines and the 15 tests on tricyclic antidepressants showed deficits in attention and information processing. Dr. Tannenbaum’s findings support the recommendation issued in the Revised Beers Criteria published last spring 2012 by the American Geriatrics Society that all sleeping pills, 1st generation antihistamines and tricyclic antidepressants should be avoided at all costs in seniors.

Dr. Tannenbaum believes in the importance of communicating this knowledge to patients: “Seniors can play an important role in reducing the risks associated with these medications. Patients need this information so that they are more comfortable talking to their doctors and pharmacists about safer pharmacological or non-pharmacological treatment options,” she explained. She also points out that each case must be addressed on an individual basis: “Despite the known risks, it may be better for some patients to continue their medication instead of having to live with intolerable symptoms. Each individual has a right to make an informed choice based on preference and a thorough understanding of the effects the medications may have on their memory and function.”